Background: Acute human parvovirus B19 (B19) infection induces systemic lupus erythematosus (SLE)-like symptoms. It has been controversial whether B19 infection causes SLE and rheumatoid arthritis (RA). Objectives: This study prospectively investigated whether symptoms of B19 infection persisted for more than 2 years and whether persistent symptoms contributed to the development of SLE and RA. Methods: In this prospective study, clinical findings were examined and laboratory examinations were performed in 42 adult patients 1, 2, 6, 12 and 24 months after the first consultation. Results: Most acute symptoms disappeared within 2 weeks. However, arthralgia continued for 2 months in 2 women, 6 months in 1 woman and more than 2 years in 1 woman with positive antinuclear antibody and hypocomplementemia. The clinical findings of the patient with persistent arthralgia did not fulfill the criteria for SLE and RA. Conclusion: The symptoms caused by B19 infection were transient in most cases but persisted in 1 case in our series.

Keywords:
Antinuclear antibody, Erythema infectiosum, Human parvovirus B19, Rheumatoid arthritis, Systemic lupus erythematosus
1.
Seishima M, Kanoh H, Izumi T: The spectrum of cutaneous eruptions in 22 patients with isolated serological evidence of infection by parvovirus B19. Arch Dermatol 1999;135:1556–1557.
2.
Nesher G, Osborn TG, Moore TL: Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum 1995;24:297–303.
3.
Reitblat T, Drogenikov T, Sigalov I, Oren S, London D: Transient anticardiolipin antibody syndrome in a patient with parvovirus B19 infection. Am J Med 2001;109:512–513.
4.
Soloninka CA, Anderson MJ, Laskin CA: Anti-DNA and antilymphocyte antibodies during acute infection with human parvovirus B19. J Rheumatol 1989;16:777–781.
5.
Kalish RA, Knopf AN, Gary GW, Canoso JJ: Lupus-like presentation of human parvovirus B19 infection. J Rheumatol 1992;19:169–171.
6.
Sasaki T, Takahashi Y, Yoshinaga K, Sugamura K: An association between human parvovirus B19 infection and autoantibody production. J Rheumatol 1989;16:708–709.
7.
Cope AP, Jones A, Brozovic M, Shafi MS, Maini RN: Possible induction of systemic lupus erythematosus by human parvovirus. Ann Rheum Dis 1992;51:803–804.
8.
Tanaka A, Sugawara A, Sawai K, Kuwahara T: Human parvovirus B19 infection resembling systemic lupus erythematosus. Intern Med 1998;37:708–710.
9.
Trapani S, Ermini M, Falcini F: Human parvovirus B19 infection: Its relationship with systemic lupus erythematosus. Semin Arthritis Rheum 1999;28:319–325.
10.
Bengtsson A, Widell A, Elmstahl S, Sturfelt G: No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19. Ann Rheum Dis 2000;59:64–66.
11.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthritis Rheum 1982;25:1271–1277.
12.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.
13.
Vigeant P, Menard HA, Boire G: Chronic modulation of the autoimmune response following parvovirus B19 infection. J Rheumatol 1994;21:1165–1167.
14.
Cohen BJ, Buckley MM, Clewley JP, Jones VE, Puttick AH, Jacoby RK: Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis 1986;45:832–838.
15.
Gran JT, Johnsen V, Myklebust G, Nordbø SA: The variable clinical picture of arthritis induced by human parvovirus B19. Scand J Rheumatol 1995;24:174–179.
16.
Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, Caul O, Dieppe PA: Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989;149:1153–1156.
17.
Naides SJ, Scharosch LL, Foto F, Howard EJ: Rheumatologic manifestations of human parvovirus B19 infection in adults: Initial two-year clinical experience. Arthritis Rheum 1990;33:1297–1309.
18.
Harrison B, Silman A, Barrett E, Symmons D: Low frequency of recent parvovirus infection in a population-based cohort of patients with early inflammatory polyarthritis. Ann Rheum Dis 1998;57:375–377.
19.
Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, Saitoh T, Sawai T, Sugamura K, Sasaki T: Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 1998;95:8227–8232.
20.
Saal JG, Steidle M, Einsele H, Müller CA, Fritz P, Zacher J: Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992;123:147–151.
21.
Söderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K: Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997;349:1063–1065.
22.
Kerr JR, Cartron JP, Curran MD, Moore JE, Elliott JRM, Mollan RAB: A study of the role of parvovirus B19 in rheumatoid arthritis. Br J Rheumatol 1995;34:809–813.
23.
Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese M, Young NS: Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989;84:1114–1123.
24.
Moore TL: Parvovirus-associated arthritis. Curr Opin Rheumatol 2000;12:289–294.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.